The purpose of the work was to rise of biosynthesis of the human recombinant interleukin-7 (rIL-7) in E. coli by optimizing the quantitative and qualitative composition of the culture medium. As a result of optimization of the quantitative composition of organic and mineral components of the culture medium using the matrix of planning a fractional factor experiment, it was possible to increase the synthesis of rIL-7 by 1.3 times. It was proved that the use of supplements to the culture medium in the form of extracts of Clivia miniata and Zephyranthes grandiflora (0.5-1.0%) stimulated the rIL-7 synthesis in recombinant bacterial cells in 1.3-1.4 times. The use of phytoextracts at a concentration of 5.0% and more caused an inhibitory effect on the producer biosynthetic properties. It has been established that the modulation of the biosynthetic activity of recombinant bacteria is due to the interaction of the biologically active substances of plant extracts with the surface structures of the bacterial cell, namely, porins (OmpC and OmpF proteins). The stimulating effect of vitamin K1 (15-25 mg per 1 ml of culture medium) in the liposomal form was proved; such approach allowed increasing the synthesis of rIL-7 in 1.34-1.39 times. And the use of liposomal form of plant extracts as an approach to increasing the bioavailability of biologically active substances is not appropriate.
Background. Quality management is a very important activity of any industrial enterprise, especially when it comes to manufacturing products in health care (drugs, including medical immunobiological preparations, medical devices, cosmetics, dietary supplements, etc.). Risk-oriented thinking enables an organization to identify factors that may cause rejection of its processes and its quality management system for planned results to establish preventive controls to minimize negative impacts and the greatest possible shaft advantage of the opportunities as they arise. The logical continuation of the risk assessment is validation processes. This article is a fragment of the complex scientific and technical work on the development and standardization of biotechnology products based on recombinant human interleukin-7 (rhIL-7). Objective. Justification for approaches to risk assessment in the technology for getting preparation based on rhIL-7 in the form of nasal spray and particularly risk assessment of the production process, and perspective validation of developed technologies. Methods. The methodology of risk assessment according to ISO 14971:2009 "Medical devices. Guidelines for risk management" was used. Pharmacopoeial methods were used to control the process and product quality (potentiometric determination of pH, osmolality, sterility). The integrity of the filters was determined by the method according to the manometer producer. Results. The work consistently study approaches to risk assessment in the technology for getting preparation based on rhIL-7 in the form of nasal spray and particularly risk assessment of the production process, and the validation of promising technologies developed. Selection of guidelines on risk assessment was conducted for Guidelines for Good Manufacturing Practices, ISO 9001:2015, ISO 13485:2005, and ISO 14971:2009. The greater acceptability of the use of the past two standards was showed. Technological production scheme is presented and qualitative approach to analyze the identified risks is applied. For the most critical stage of production (preparation of sterile solution) the validation process is conducted. Conclusions. The feasibility of risk assessment in the technology for getting preparation based on rhIL-7 in the form of nasal spray according to ISO 14971:2009 together with the system using risk analysis and critical control points is theoretically justified. It was found that the most critical step in the production is part of the preparation of a sterile solution, which includes the preparation of intermediate filtering and sterilizing drug. The conducted prospective validation of the most critical stages of the technology demonstrated its stability and compliance with established eligibility criteria.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.